share_log

bluebird bio analyst ratings

bluebird bio analyst ratings

蓝鸟生物分析师评级
Benzinga Analyst Ratings ·  2022/08/06 01:35
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
08/05/2022 -11.51% Barclays $3 → $5 Upgrades Underweight → Equal-Weight
08/02/2022 41.59% Raymond James → $8 Upgrades Market Perform → Outperform
05/24/2022 -64.6% Goldman Sachs $3 → $2 Maintains Sell
05/17/2022 -46.9% Morgan Stanley $5 → $3 Maintains Underweight
05/10/2022 -46.9% Barclays $4 → $3 Maintains Underweight
04/06/2022 — Cowen & Co. Downgrades Outperform → Market Perform
04/06/2022 41.59% SVB Leerink $10 → $8 Maintains Market Perform
03/08/2022 41.59% Wells Fargo $12 → $8 Maintains Equal-Weight
03/07/2022 -11.51% Morgan Stanley $6 → $5 Maintains Underweight
03/07/2022 -29.21% Barclays $13 → $4 Downgrades Equal-Weight → Underweight
03/07/2022 76.98% SVB Leerink $11 → $10 Maintains Market Perform
01/06/2022 76.98% Morgan Stanley $11 → $10 Maintains Underweight
11/08/2021 76.98% Goldman Sachs $23 → $10 Downgrades Neutral → Sell
11/08/2021 130.08% Barclays $20 → $13 Maintains Equal-Weight
11/08/2021 94.68% Morgan Stanley → $11 Downgrades Equal-Weight → Underweight
09/22/2021 307.07% Mizuho $29 → $23 Maintains Buy
08/10/2021 253.97% Canaccord Genuity $86 → $20 Downgrades Buy → Hold
08/10/2021 307.07% Goldman Sachs $63 → $23 Downgrades Buy → Neutral
08/10/2021 342.46% Wells Fargo $60 → $25 Downgrades Overweight → Equal-Weight
07/16/2021 519.45% Morgan Stanley $36 → $35 Maintains Equal-Weight
07/01/2021 519.45% Berenberg → $35 Downgrades Buy → Hold
04/19/2021 537.15% Morgan Stanley $45 → $36 Maintains Equal-Weight
03/29/2021 1174.29% SVB Leerink $69 → $72 Maintains Outperform
03/10/2021 1121.2% Mizuho $34 → $69 Upgrades Neutral → Buy
03/02/2021 696.43% Morgan Stanley $50 → $45 Maintains Equal-Weight
02/17/2021 590.24% JP Morgan $76 → $39 Downgrades Overweight → Neutral
11/11/2020 1032.7% Berenberg → $64 Initiates Coverage On → Buy
11/11/2020 784.92% Morgan Stanley $68 → $50 Maintains Equal-Weight
11/05/2020 873.42% Piper Sandler $70 → $55 Maintains Neutral
11/05/2020 1333.58% B of A Securities $100 → $81 Maintains Buy
11/05/2020 1652.15% SVB Leerink $133 → $99 Maintains Outperform
11/05/2020 891.12% BMO Capital → $56 Downgrades Outperform → Market Perform
10/20/2020 2076.91% Mizuho → $123 Initiates Coverage On → Buy
08/10/2020 1103.5% Morgan Stanley $73 → $68 Maintains Equal-Weight
08/06/2020 1811.44% BMO Capital $112 → $108 Maintains Outperform
08/06/2020 1333.58% Wedbush $89 → $81 Maintains Outperform
07/13/2020 1669.85% B of A Securities $104 → $100 Maintains Buy
06/12/2020 2253.9% SVB Leerink $129 → $133 Maintains Outperform
05/28/2020 1191.99% Morgan Stanley $69 → $73 Maintains Equal-Weight
05/28/2020 2183.11% SVB Leerink $125 → $129 Maintains Outperform
05/13/2020 1669.85% RBC Capital → $100 Initiates Coverage On → Outperform
05/12/2020 1882.23% BMO Capital $107 → $112 Maintains Outperform
04/15/2020 1121.2% Morgan Stanley $92 → $69 Maintains Equal-Weight
03/27/2020 1138.89% Stifel $94 → $70 Upgrades Hold → Buy
02/26/2020 1528.26% Morgan Stanley $100 → $92 Maintains Equal-Weight
02/19/2020 1563.66% Stifel $96 → $94 Maintains Hold
02/03/2020 1669.85% Evercore ISI Group $86 → $100 Upgrades In-Line → Outperform
12/13/2019 2289.3% Oppenheimer → $135 Upgrades Perform → Outperform
12/09/2019 2731.76% Wells Fargo $242 → $160 Maintains Overweight
11/26/2019 2006.12% SVB Leerink → $119 Upgrades Market Perform → Outperform
11/19/2019 1422.07% Evercore ISI Group → $86 Downgrades Outperform → In-Line
11/04/2019 — Wedbush Upgrades Neutral → Outperform
11/01/2019 1404.37% Piper Sandler $120 → $85 Maintains Neutral
11/01/2019 1669.85% Morgan Stanley $104 → $100 Maintains Equal-Weight
10/11/2019 1740.64% Morgan Stanley $136 → $104 Maintains Equal-Weight
10/01/2019 1829.14% Stifel → $109 Initiates Coverage On → Hold
08/12/2019 — William Blair Downgrades Outperform → Market Perform
08/06/2019 2306.99% Morgan Stanley $143 → $136 Maintains Equal-Weight
06/18/2019 2731.76% Maxim Group → $160 Upgrades Hold → Buy
06/17/2019 2784.85% BMO Capital $191 → $163 Maintains Outperform
05/15/2019 2218.5% Wedbush $166 → $131 Downgrades Outperform → Neutral
03/05/2019 — Leerink Swann Downgrades Outperform → Market Perform
02/26/2019 — Cowen & Co. Initiates Coverage On → Outperform
01/23/2019 2749.46% Canaccord Genuity $250 → $161 Maintains Buy
12/20/2018 — Raymond James Initiates Coverage On → Strong Buy
12/19/2018 2112.31% Morgan Stanley $185 → $125 Maintains Equal-Weight
12/06/2018 2023.82% Piper Sandler $240 → $120 Downgrades Overweight → Neutral
11/28/2018 2466.28% Leerink Swann → $145 Initiates Coverage On → Outperform
11/05/2018 3174.22% Morgan Stanley $186 → $185 Maintains Equal-Weight
11/05/2018 2837.95% Wedbush $204 → $166 Maintains Outperform
11/05/2018 2908.74% Janney Montgomery Scott $170 → $170 Upgrades Neutral → Buy
10/15/2018 3191.92% Morgan Stanley $190 → $186 Maintains Equal-Weight
06/19/2018 3970.65% Evercore ISI Group $175 → $230 Upgrades In-Line → Outperform
05/31/2018 4147.64% Piper Sandler → $240 Assumes Overweight → Overweight
05/03/2018 3722.87% BMO Capital $222 → $216 Maintains Outperform
03/21/2018 3598.98% Morgan Stanley $152 → $209 Maintains Equal-Weight
03/14/2018 3793.67% Janney Montgomery Scott → $220 Initiates Coverage On → Neutral
03/05/2018 4183.03% William Blair → $242 Initiates Coverage On → Outperform
02/26/2018 2590.17% Morgan Stanley $151 → $152 Maintains Equal-Weight
02/22/2018 3758.27% B of A Securities $185 → $218 Maintains Neutral
02/22/2018 3829.06% BMO Capital $215 → $222 Maintains Outperform
01/25/2018 — Leerink Swann Downgrades Outperform → Market Perform
12/21/2017 — Oppenheimer Initiates Coverage On → Perform
12/13/2017 — Maxim Group Downgrades Buy → Hold
12/11/2017 — Jefferies Upgrades Hold → Buy
12/05/2017 3475.09% Canaccord Genuity → $202 Initiates Coverage On → Buy
11/30/2017 3439.7% Maxim Group $170 → $200 Maintains Buy
11/06/2017 — Evercore ISI Group Downgrades Outperform → In-Line
11/03/2017 2784.85% SunTrust Robinson Humphrey $108 → $163 Maintains Buy
11/03/2017 — Morgan Stanley Upgrades Underweight → Equal-Weight
11/02/2017 2767.16% Barclays $151 → $162 Maintains Overweight
11/02/2017 — BTIG Upgrades Neutral → Buy
10/30/2017 2767.16% BMO Capital $134 → $162 Maintains Outperform
10/16/2017 — Evercore ISI Group Upgrades In-Line → Outperform
10/11/2017 — Jefferies Downgrades Buy → Hold
10/02/2017 — Morgan Stanley Downgrades Equal-Weight → Underweight
09/07/2017 2572.47% Barclays → $151 Initiates Coverage On → Overweight
08/17/2017 1705.25% Evercore ISI Group → $102 Initiates Coverage On → In-Line
08/07/2017 1758.34% Morgan Stanley $103 → $105 Maintains Equal-Weight
日期 上行/下行 分析公司 目标价格变化 评级变化 上一次/当前评级
08/05/2022 -11.51% 巴克莱 $3 → $5 升级 重量不足的→等重
08/02/2022 41.59% 雷蒙德·詹姆斯 → $8 升级 市场表现优于→
05/24/2022 -64.6% 高盛 $3 → $2 维护 卖
05/17/2022 -46.9% 摩根士丹利 $5 → $3 维护 体重不足
05/10/2022 -46.9% 巴克莱 $4 → $3 维护 体重不足
04/06/2022 — 考恩公司 评级下调 跑赢→市场表现
04/06/2022 41.59% SVB Leerink $10 → $8 维护 市场表现
03/08/2022 41.59% 富国银行 $12 → $8 维护 等重
03/07/2022 -11.51% 摩根士丹利 $6 → $5 维护 体重不足
03/07/2022 -29.21% 巴克莱 $13 → $4 评级下调 等重→减码
03/07/2022 76.98% SVB Leerink $11 → $10 维护 市场表现
01/06/2022 76.98% 摩根士丹利 $11 → $10 维护 体重不足
11/08/2021 76.98% 高盛 $23 → $10 评级下调 中性→销售
11/08/2021 130.08% 巴克莱 $20 → $13 维护 等重
11/08/2021 94.68% 摩根士丹利 → $11 评级下调 等重→减码
09/22/2021 307.07% 瑞穗 $29 → $23 维护 买
08/10/2021 253.97% 卡纳科特·格纳奇 $86 → $20 评级下调 购买→Hold
08/10/2021 307.07% 高盛 $63 → $23 评级下调 购买→中性
08/10/2021 342.46% 富国银行 $60 → $25 评级下调 超重→等重
07/16/2021 519.45% 摩根士丹利 $36 → $35 维护 等重
07/01/2021 519.45% 贝伦伯格 → $35 评级下调 购买→Hold
04/19/2021 537.15% 摩根士丹利 $45 → $36 维护 等重
03/29/2021 1174.29% SVB Leerink $69 → $72 维护 跑赢大盘
03/10/2021 1121.2% 瑞穗 $34 → $69 升级 中性→购买
03/02/2021 696.43% 摩根士丹利 $50 → $45 维护 等重
02/17/2021 590.24% 摩根大通 $76 → $39 评级下调 超重→中性
11/11/2020 1032.7% 贝伦伯格 → $64 开始承保 →购买
11/11/2020 784.92% 摩根士丹利 $68 → $50 维护 等重
11/05/2020 873.42% 派珀·桑德勒 $70 → $55 维护 中性
11/05/2020 1333.58% B of A证券 $100 → $81 维护 买
11/05/2020 1652.15% SVB Leerink $133 → $99 维护 跑赢大盘
11/05/2020 891.12% 蒙特利尔银行资本 → $56 评级下调 跑赢→市场表现
10/20/2020 2076.91% 瑞穗 → $123 开始承保 →购买
08/10/2020 1103.5% 摩根士丹利 $73 → $68 维护 等重
08/06/2020 1811.44% 蒙特利尔银行资本 $112 → $108 维护 跑赢大盘
08/06/2020 1333.58% 韦德布什 $89 → $81 维护 跑赢大盘
07/13/2020 1669.85% B of A证券 $104 → $100 维护 买
06/12/2020 2253.9% SVB Leerink $129 → $133 维护 跑赢大盘
05/28/2020 1191.99% 摩根士丹利 $69 → $73 维护 等重
05/28/2020 2183.11% SVB Leerink $125 → $129 维护 跑赢大盘
05/13/2020 1669.85% 加拿大皇家银行资本 → $100 开始承保 →跑赢大盘
05/12/2020 1882.23% 蒙特利尔银行资本 $107 → $112 维护 跑赢大盘
04/15/2020 1121.2% 摩根士丹利 $92 → $69 维护 等重
03/27/2020 1138.89% Stifel $94 → $70 升级 持有→购买
02/26/2020 1528.26% 摩根士丹利 $100 → $92 维护 等重
02/19/2020 1563.66% Stifel $96 → $94 维护 保持
02/03/2020 1669.85% Evercore ISI集团 $86 → $100 升级 线内→表现优异
12/13/2019 2289.3% 奥本海默 → $135 升级 →表现强于大盘
12/09/2019 2731.76% 富国银行 $242 → $160 维护 超重
11/26/2019 2006.12% SVB Leerink → $119 升级 市场表现优于→
11/19/2019 1422.07% Evercore ISI集团 → $86 评级下调 胜过→同线
11/04/2019 — 韦德布什 升级 中性→表现优异
11/01/2019 1404.37% 派珀·桑德勒 $120 → $85 维护 中性
11/01/2019 1669.85% 摩根士丹利 $104 → $100 维护 等重
10/11/2019 1740.64% 摩根士丹利 $136 → $104 维护 等重
10/01/2019 1829.14% Stifel → $109 开始承保 →保留
08/12/2019 — 威廉·布莱尔 评级下调 跑赢→市场表现
08/06/2019 2306.99% 摩根士丹利 $143 → $136 维护 等重
06/18/2019 2731.76% Maxim集团 → $160 升级 持有→购买
06/17/2019 2784.85% 蒙特利尔银行资本 $191 → $163 维护 跑赢大盘
05/15/2019 2218.5% 韦德布什 $166 → $131 评级下调 跑赢→中性
03/05/2019 — 利林克·斯旺 评级下调 跑赢→市场表现
02/26/2019 — 考恩公司 开始承保 →跑赢大盘
01/23/2019 2749.46% 卡纳科特·格纳奇 $250 → $161 维护 买
12/20/2018 — 雷蒙德·詹姆斯 开始承保 →强势购买
12/19/2018 2112.31% 摩根士丹利 $185 → $125 维护 等重
12/06/2018 2023.82% 派珀·桑德勒 $240 → $120 评级下调 超重→中性
11/28/2018 2466.28% 利林克·斯旺 → $145 开始承保 →跑赢大盘
11/05/2018 3174.22% 摩根士丹利 $186 → $185 维护 等重
11/05/2018 2837.95% 韦德布什 $204 → $166 维护 跑赢大盘
11/05/2018 2908.74% 詹尼·蒙哥马利·斯科特 $170 → $170 升级 中性→购买
10/15/2018 3191.92% 摩根士丹利 $190 → $186 维护 等重
06/19/2018 3970.65% Evercore ISI集团 $175 → $230 升级 线内→表现优异
05/31/2018 4147.64% 派珀·桑德勒 → $240 假设 超重→超重
05/03/2018 3722.87% 蒙特利尔银行资本 $222 → $216 维护 跑赢大盘
03/21/2018 3598.98% 摩根士丹利 $152 → $209 维护 等重
03/14/2018 3793.67% 詹尼·蒙哥马利·斯科特 → $220 开始承保 →中性
03/05/2018 4183.03% 威廉·布莱尔 → $242 开始承保 →跑赢大盘
02/26/2018 2590.17% 摩根士丹利 $151 → $152 维护 等重
02/22/2018 3758.27% B of A证券 $185 → $218 维护 中性
02/22/2018 3829.06% 蒙特利尔银行资本 $215 → $222 维护 跑赢大盘
01/25/2018 — 利林克·斯旺 评级下调 跑赢→市场表现
12/21/2017 — 奥本海默 开始承保 →性能
12/13/2017 — Maxim集团 评级下调 购买→Hold
12/11/2017 — 杰富瑞 升级 持有→购买
12/05/2017 3475.09% 卡纳科特·格纳奇 → $202 开始承保 →购买
11/30/2017 3439.7% Maxim集团 $170 → $200 维护 买
11/06/2017 — Evercore ISI集团 评级下调 胜过→同线
11/03/2017 2784.85% SunTrust Robinson Humphrey $108 → $163 维护 买
11/03/2017 — 摩根士丹利 升级 重量不足的→等重
11/02/2017 2767.16% 巴克莱 $151 → $162 维护 超重
11/02/2017 — BTIG 升级 中性→购买
10/30/2017 2767.16% 蒙特利尔银行资本 $134 → $162 维护 跑赢大盘
10/16/2017 — Evercore ISI集团 升级 线内→表现优异
10/11/2017 — 杰富瑞 评级下调 购买→Hold
10/02/2017 — 摩根士丹利 评级下调 等重→减码
09/07/2017 2572.47% 巴克莱 → $151 开始承保 →超重
08/17/2017 1705.25% Evercore ISI集团 → $102 开始承保 →串联
08/07/2017 1758.34% 摩根士丹利 $103 → $105 维护 等重

bluebird bio Questions & Answers

青鸟传记问答

What is the target price for bluebird bio (BLUE)?
蓝鸟生物(蓝色)的目标价格是多少？

The latest price target for bluebird bio (NASDAQ: BLUE) was reported by Barclays on August 5, 2022. The analyst firm set a price target for $5.00 expecting BLUE to fall to within 12 months (a possible -11.51% downside). 19 analyst firms have reported ratings in the last year.

巴克莱银行于2022年8月5日报道了蓝鸟生物(纳斯达克：蓝色)的最新目标价。这家分析公司将目标价定为5美元，预计蓝色将在12个月内跌至(可能下跌11.51%)。去年有19家分析公司公布了评级。

What is the most recent analyst rating for bluebird bio (BLUE)?
蓝鸟生物(蓝色)的最新分析师评级是多少？

The latest analyst rating for bluebird bio (NASDAQ: BLUE) was provided by Barclays, and bluebird bio upgraded their equal-weight rating.

蓝鸟生物(纳斯达克：蓝)的最新分析师评级由巴克莱提供，蓝鸟生物上调了其同等权重的评级。

When is the next analyst rating going to be posted or updated for bluebird bio (BLUE)?
蓝鸟生物(蓝色)的下一次分析师评级将于何时发布或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of bluebird bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for bluebird bio was filed on August 5, 2022 so you should expect the next rating to be made available sometime around August 5, 2023.

分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与蓝鸟生物的高管和客户交谈，以及收听收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。蓝鸟生物的上一次评级是在2022年8月5日提交的，所以你应该预计下一次评级将在2023年8月5日左右的某个时候提供。

Is the Analyst Rating bluebird bio (BLUE) correct?
分析师对蓝鸟生物(蓝色)的评级正确吗？

While ratings are subjective and will change, the latest bluebird bio (BLUE) rating was a upgraded with a price target of $3.00 to $5.00. The current price bluebird bio (BLUE) is trading at is $5.65, which is out of the analyst's predicted range.

虽然评级是主观的，并将发生变化，但最新的蓝鸟生物(蓝色)评级被上调，目标价从3.00美元到5.00美元。蓝鸟生物(Blue)目前的交易价格为5.65美元，超出了分析师的预测区间。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发